Shanghai, China-based Arctic Vision has entered into an agreement to acquire the ophthalmic device business of MDCO Technology, a Hangzhou, China-based ophthalmic medical-device company.

Financial terms of the deal were not disclosed.

The proposed transaction will bring MDCO’s premium IOL, implantable contact lens (phakic lens), and refractive-device platforms into Arctic Vision’s global ophthalmic innovation framework. 

Arctic Vision’s R&D capabilities in retinal diseases, ocular surface disorders, and neuro-ophthalmology will be complemented by MDCO’s design and manufacturing expertise in IOL and phakic lens technologies, according to Artic Vision. Together, the combined platform aims to deliver differentiated solutions across the ophthalmology value chain, from discovery and development to manufacturing and global commercialization.

Under the terms of the transaction, MDCO will become a wholly owned subsidiary of Arctic Vision. The group will continue to operate across key global hubs, including Shanghai for biopharmaceutical R&D, regulatory affairs, and operations; Hangzhou for implanted-device R&D, manufacturing, and commercial management; and California for design innovation and global collaboration.

“This transaction represents a pivotal step for Arctic Vision’s long-term growth strategy,” said Dr. Eddy Wu, Founder, Chairman, and CEO of Arctic Vision. “Through the integration of MDCO’s ophthalmic device platforms with Arctic Vision’s pharmaceutical innovation capabilities, we are establishing a truly comprehensive ophthalmic innovation ecosystem—one that integrates scientific excellence with advanced manufacturing and commercial scale. Looking ahead, we are building a company structurally prepared for broader global investment participation and future capital-market opportunities, while expanding our ability to reach more patients and deliver greater impact across the ophthalmology community worldwide.”